(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.
Rani Therapeutics Holdings's earnings in 2026 is -$29,673,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$26,074,334, with the lowest RANI earnings forecast at -$36,365,532, and the highest RANI earnings forecast at -$16,883,997. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$25,233,226, with the lowest RANI earnings forecast at -$29,092,426, and the highest RANI earnings forecast at -$23,377,842.
In 2028, RANI is forecast to generate -$27,756,549 in earnings, with the lowest earnings forecast at -$29,092,426 and the highest earnings forecast at -$25,975,380.